On Monday, Cardiff Oncology Inc (NASDAQ: CRDF) opened lower -4.48% from the last session, before settling in for the closing price of $2.90. Price fluctuations for CRDF have ranged from $0.94 to $6.42 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 9.26% over the past five years. Company’s average yearly earnings per share was noted -7.72% at the time writing. With a float of $42.94 million, this company’s outstanding shares have now reached $44.68 million.
Let’s look at the performance matrix of the company that is accounted for 32 employees. In terms of profitability, gross margin is 37.29%, operating margin of -6711.28%, and the pretax margin is -6143.91%.
Cardiff Oncology Inc (CRDF) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Cardiff Oncology Inc is 7.76%, while institutional ownership is 28.05%. The most recent insider transaction that took place on Dec 19 ’23, was worth 41,100. In this transaction Director of this company bought 30,000 shares at a rate of $1.37, taking the stock ownership to the 697,761 shares.
Cardiff Oncology Inc (CRDF) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.22 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.28) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -7.72% per share during the next fiscal year.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
Check out the current performance indicators for Cardiff Oncology Inc (CRDF). In the past quarter, the stock posted a quick ratio of 4.97. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 192.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.91, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -1.04 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
Cardiff Oncology Inc (NASDAQ: CRDF) saw its 5-day average volume 0.82 million, a negative change from its year-to-date volume of 0.94 million. As of the previous 9 days, the stock’s Stochastic %D was 58.61%. Additionally, its Average True Range was 0.19.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 58.02%, which indicates a significant increase from 40.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.77% in the past 14 days, which was lower than the 66.50% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.49, while its 200-day Moving Average is $2.93. Nevertheless, the first resistance level for the watch stands at $2.89 in the near term. At $3.00, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.11. If the price goes on to break the first support level at $2.67, it is likely to go to the next support level at $2.56. Assuming the price breaks the second support level, the third support level stands at $2.45.
Cardiff Oncology Inc (NASDAQ: CRDF) Key Stats
There are currently 44,725K shares outstanding in the company with a market cap of 128.94 million. Presently, the company’s annual sales total 490 K according to its annual income of -41,440 K. Last quarter, the company’s sales amounted to 160 K and its income totaled -11,780 K.
